{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:57:40Z","timestamp":1791575860119,"version":"4.3.4"},"reference-count":118,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Therapeutic peptides are oligomers or short polymers of amino acids used for various medical purposes. Peptide-based treatments have evolved considerably due to new technologies, stimulating new research interests. They have been shown to be beneficial in a variety of therapeutic applications, notably in the treatment of cardiovascular disorders such as acute coronary syndrome (ACS). ACS is characterized by coronary artery wall damage and consequent formation of an intraluminal thrombus obstructing one or more coronary arteries, leading to unstable angina, non-ST elevated myocardial infarction, and ST-elevated myocardial infarction. One of the promising peptide drugs in the treatment of these pathologies is eptifibatide, a synthetic heptapeptide derived from rattlesnake venom. Eptifibatide is a glycoprotein IIb\/IIIa inhibitor that blocks different pathways in platelet activation and aggregation. In this narrative review, we summarized the current evidence on the mechanism of action, clinical pharmacology, and applications of eptifibatide in cardiology. Additionally, we illustrated its possible broader usage with new indications, including ischemic stroke, carotid stenting, intracranial aneurysm stenting, and septic shock. Further research is, however, required to fully evaluate the role of eptifibatide in these pathologies, independently and in comparison to other medications.<\/jats:p>","DOI":"10.3390\/ijms24065446","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T05:36:21Z","timestamp":1678685781000},"page":"5446","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8268-1695","authenticated-orcid":false,"given":"Ga\u0161per","family":"Tonin","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Faculty of Arts, University of Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasna","family":"Klen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia"},{"name":"Division of Surgery, Department of Abdominal Surgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","article-title":"Synthetic therapeutic peptides: Science and market","volume":"15","author":"Vlieghe","year":"2010","journal-title":"Drug Discov. Today"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40262-013-0079-0","article-title":"Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides","volume":"52","author":"Diao","year":"2013","journal-title":"Clin. Pharm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: Current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1021\/acs.jmedchem.7b00318","article-title":"The current state of peptide drug discovery: Back to the future?","volume":"61","author":"Henninot","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: Historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorganic Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.2174\/0929866525666181114155542","article-title":"Building on success: A bright future for peptide therapeutics","volume":"25","author":"Angell","year":"2018","journal-title":"Protein Pept. Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40290-018-0261-7","article-title":"Peptide-based therapeutics for oncology","volume":"33","author":"Fisher","year":"2019","journal-title":"Pharm. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/1753-0407.12969","article-title":"Review of Glucagon-Like Peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects","volume":"11","author":"Sloan","year":"2019","journal-title":"J. Diabetes"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1573399813666170414101450","article-title":"Effect of Glucagon-like Peptide-1 receptor agonists on all-cause mortality and cardiovascular outcomes: A meta-analysis","volume":"14","author":"Peterson","year":"2018","journal-title":"Curr. Diabetes Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.2174\/0929867327666200908112847","article-title":"Monoclonal antibodies, small molecule inhibitors and antibody-drug conjugates as HER2 inhibitors","volume":"28","author":"Li","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1002\/hed.25832","article-title":"Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis","volume":"41","author":"Vuong","year":"2019","journal-title":"Head Neck"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1021\/acs.molpharmaceut.9b00308","article-title":"Glucagon-Like Peptide-1 receptor agonists and strategies to improve their efficiency","volume":"16","author":"Alavi","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1021\/acs.joc.0c00104","article-title":"Modern peptide and protein chemistry: Reaching new heights","volume":"85","author":"Hackenberger","year":"2020","journal-title":"J. Org. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCRESAHA.117.308903","article-title":"Reducing the global burden of cardiovascular disease, part 1: The epidemiology and risk factors","volume":"121","author":"Joseph","year":"2017","journal-title":"Circ. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1007\/s00216-018-0925-x","article-title":"peptidomic strategy for purification and identification of potential ACE-inhibitory and antioxidant peptides in tetradesmus obliquus microalgae","volume":"410","author":"Montone","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","article-title":"Cardiac natriuretic peptides","volume":"17","author":"Goetze","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.abb.2018.11.021","article-title":"Natural and synthetic peptides in the cardiovascular diseases: An update on diagnostic and therapeutic potentials","volume":"662","author":"Grieco","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3389\/fphar.2016.00526","article-title":"The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease","volume":"7","author":"Recio","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_20","first-page":"197","article-title":"Hemostaza","volume":"56","author":"Lenasi","year":"2017","journal-title":"Med. Razgl."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Scridon, A. (2022). Platelets and their role in hemostasis and thrombosis\u2014From physiology to pathophysiology and therapeutic implications. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112772"},{"key":"ref_22","unstructured":"LaPelusa, A., and Dave, H.D. (2022). StatPearls, StatPearls."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/rth2.12107","article-title":"Integrating platelet and coagulation activation in fibrin clot formation","volume":"2","author":"Swieringa","year":"2018","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1160\/TH16-12-0911","article-title":"Platelet receptors as therapeutic targets: Past, present and future","volume":"117","author":"Jamasbi","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.drudis.2014.06.005","article-title":"New Advances in treating thrombotic diseases: GPVI as a platelet drug target","volume":"19","author":"Jiang","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1161\/ATVBAHA.114.303413","article-title":"Current State and Novel Approaches of Antiplatelet Therapy","volume":"35","author":"Metharom","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_27","unstructured":"Bansal, A.B., Sattar, Y., and Jamil, R.T. (2022). StatPearls, StatPearls."},{"key":"ref_28","unstructured":"Sampat, P.J., and Wadhwa, R. (2022). StatPearls, StatPearls."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1161\/CIRCULATIONAHA.109.921502","article-title":"Prasugrel","volume":"122","author":"Wiviott","year":"2010","journal-title":"Circulation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/14656566.2017.1421634","article-title":"Ticagrelor in Modern Cardiology\u2014An up-to-Date Review of Most Important Aspects of Ticagrelor Pharmacotherapy","volume":"19","author":"Danielak","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_31","first-page":"78","article-title":"Ticagrelor: An Emerging Oral Antiplatelet Agent","volume":"4","author":"Juneja","year":"2013","journal-title":"J. Pharm. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e022125","DOI":"10.1161\/JAHA.121.022125","article-title":"Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives","volume":"10","author":"Steg","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_33","unstructured":"Iqbal, A.M., Lopez, R.A., and Hai, O. (2022). StatPearls, StatPearls."},{"key":"ref_34","unstructured":"Stoffer, K., Bistas, K.G., Reddy, V., and Shah, S. (2022). StatPearls, StatPearls."},{"key":"ref_35","unstructured":"Tummala, R., and Rai, M.P. (2022). StatPearls, StatPearls."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15420\/ecr.2016:34:2","article-title":"Antiplatelet Therapy in Acute Coronary Syndrome","volume":"2017 12","author":"Layne","year":"2017","journal-title":"Eur. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e001330","DOI":"10.1161\/JAHA.113.001330","article-title":"Comparative Effectiveness Review of Antiplatelet Agents in Peripheral Artery Disease","volume":"3","author":"Schmit","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4037\/ccn2010708","article-title":"Oral Antiplatelet Therapy for the Management of Acute Coronary Syndromes: Defining the Role of Prasugrel","volume":"31","author":"Devabhakthuni","year":"2011","journal-title":"Crit. Care Nurse"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","article-title":"Integrins: Bidirectional, Allosteric Signaling Machines","volume":"110","author":"Hynes","year":"2002","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-019-0709-6","article-title":"Platelet integrin AIIb\u03b23: Signal transduction, regulation, and its therapeutic targeting","volume":"12","author":"Huang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2147\/JBM.S71319","article-title":"Glanzmann\u2019s thrombasthenia: Pathogenesis, diagnosis, and current and emerging treatment options","volume":"6","author":"Solh","year":"2015","journal-title":"J. Blood Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3324\/haematol.2018.191700","article-title":"NLRP3 regulates platelet integrin AIIb\u03b23 outside-in signaling, hemostasis and arterial thrombosis","volume":"103","author":"Qiao","year":"2018","journal-title":"Haematologica"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/cge.13366","article-title":"Clinical and molecular insights into glanzmann\u2019s thrombasthenia in China","volume":"94","author":"Zhou","year":"2018","journal-title":"Clin. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/09537109975915","article-title":"Blockade of GpIIb\/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis","volume":"10","author":"Amirkhosravi","year":"1999","journal-title":"Platelets"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1538-7836.2009.03370.x","article-title":"Integrins in platelet activation","volume":"7","author":"Nieswandt","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_46","unstructured":"Ahn, J.-M., Kassees, K., Lee, T.-K., Manandhar, B., and Yousif, A.M. (2017). Comprehensive Medicinal Chemistry III, Elsevier."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Mohamed Abd El-Aziz, T., Soares, A.G., and Stockand, J.D. (2019). Snake venoms in drug discovery: Valuable therapeutic tools for life saving. Toxins, 11.","DOI":"10.3390\/toxins11100564"},{"key":"ref_48","unstructured":"(2023, March 01). Eptifibatide. DB00063. Available online: https:\/\/go.drugbank.com\/drugs\/DB00063."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0002-9343(02)01146-4","article-title":"Oral glycoprotein IIb\/IIIa inhibition\u2014Great idea, but it didn\u2019t work","volume":"112","author":"Cannon","year":"2002","journal-title":"Am. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0002-9343(02)01106-3","article-title":"The failure of orally administered glycoprotein IIb\/IIIa inhibitors to prevent recurrent cardiac events","volume":"112","author":"Newby","year":"2002","journal-title":"Am. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.102.2.149","article-title":"Oral glycoprotein IIb\/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial","volume":"102","author":"Cannon","year":"2000","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM200005043421803","article-title":"Long-Term Treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. Excite trial investigators. Evaluation of oral xemilofiban in controlling thrombotic events","volume":"342","author":"Serruys","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Second SYMPHONY Investigators (2001). Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation, 103, 1727\u20131733.","DOI":"10.1161\/01.CIR.103.13.1727"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1067\/mhj.2000.105107","article-title":"Design of the blockade of the glycoprotein IIb\/IIIa receptor to avoid vascular occlusion (BRAVO) trial","volume":"139","author":"Topol","year":"2000","journal-title":"Am. Heart J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/01.ATV.20.4.1162","article-title":"Comparative in vitro efficacy of different platelet glycoprotein IIb\/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: Differentiation among glycoprotein IIb\/IIIa antagonists","volume":"20","author":"Mousa","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1007\/s00253-016-7610-9","article-title":"Snake venom toxins: Toxicity and medicinal applications","volume":"100","author":"Chan","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Lazarovici, P., Marcinkiewicz, C., and Lelkes, P.I. (2019). From snake venom\u2019s disintegrins and C-Type lectins to anti-platelet drugs. Toxins, 11.","DOI":"10.3390\/toxins11050303"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0041-0101(95)00006-8","article-title":"Abb\u00e9 Felice Fontana (1730\u20131805): Founder of modern toxinology","volume":"33","author":"Hawgood","year":"1995","journal-title":"Toxicon"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"11B","DOI":"10.1016\/S0002-9149(97)00572-9","article-title":"Clinical pharmacology of eptifibatide","volume":"80","author":"Phillips","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"ref_60","unstructured":"Bank, R.P.D. (2023, March 01). RCSB PDB\u20147THO: Integrin AlaphIIBbeta3 Complex with Eptifibatide. Available online: https:\/\/www.rcsb.org\/structure\/7THO."},{"key":"ref_61","unstructured":"Bank, R.P.D. (2023, March 01). RCSB PDB\u20142VDN: Re-Refinement of Integrin AlphaIIbBeta3 Headpiece Bound to Antagonist Eptifibatide. Available online: https:\/\/www.rcsb.org\/structure\/2VDN."},{"key":"ref_62","unstructured":"Bank, R.P.D. (2023, March 01). RCSB PDB\u20147U60: Integrin AlaphIIBbeta3 Complex with CRGDfV. Available online: https:\/\/www.rcsb.org\/structure\/7U60."},{"key":"ref_63","unstructured":"(2023, January 09). PubChem Eptifibatide, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/123610."},{"key":"ref_64","unstructured":"(2023, March 01). Disintegrin Barbourin\u2014Sistrurus Miliarius Barbouri (Dusky Pigmy Rattlesnake) | UniProtKB | UniProt. Available online: https:\/\/www.uniprot.org\/uniprotkb\/P22827\/entry."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0021-9258(18)54042-4","article-title":"Design of potent and specific integrin antagonists. peptide antagonists with high specificity for glycoprotein IIb-IIIa","volume":"268","author":"Scarborough","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/cpdd.717","article-title":"Clinical evaluation of the tolerability, pharmacokinetics, and inhibition of platelet aggregation of eptifibatide in healthy chinese subjects","volume":"9","author":"Liu","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the european society of cardiology (ESC)","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1161\/STROKEAHA.108.517656","article-title":"The combined approach to lysis utilizing eptifibatide and Rt-PA in acute ischemic stroke: The clear stroke trial","volume":"39","author":"Pancioli","year":"2008","journal-title":"Stroke"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1161\/STROKEAHA.115.010260","article-title":"Combined approach to lysis utilizing eptifibatide and recombinant tissue-type plasminogen activator in acute ischemic stroke-full dose regimen stroke trial","volume":"46","author":"Adeoye","year":"2015","journal-title":"Stroke"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1076029620942594","DOI":"10.1177\/1076029620942594","article-title":"Safety of glycoprotein IIb-IIIa inhibitors used in stroke-related treatment: A systematic review and meta-analysis","volume":"26","author":"Zhu","year":"2020","journal-title":"Clin. Appl. Thromb.\/Hemost."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3892\/etm.2022.11721","article-title":"Treatment of progressive ischemic stroke with low-dose eptifibatide: A retrospective case-control study","volume":"25","author":"Luo","year":"2022","journal-title":"Exp. Ther. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s13054-019-2573-8","article-title":"Co-administration of iloprost and eptifibatide in septic shock (CO-ILEPSS)-a randomised, controlled, double-blind investigator-initiated trial investigating safety and efficacy","volume":"23","author":"Berthelsen","year":"2019","journal-title":"Crit. Care"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"727026","DOI":"10.3389\/fneur.2022.727026","article-title":"Safety and Efficacy of Cangrelor Among Three antiplatelet regimens during stent-assisted endovascular treatment of unruptured intracranial aneurysm: A single-center retrospective study","volume":"13","author":"Magro","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s11239-021-02584-3","article-title":"Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: A systematic review and meta-analysis of prospective studies","volume":"53","author":"Liu","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Wu, F., Ma, K., Xiang, R., Han, B., Chang, J., Zuo, Z., Luo, Y., and Mao, M. (2022). Efficacy and safety of a bridging strategy that uses intravenous platelet glycoprotein receptor inhibitors for patients undergoing surgery after coronary stent implantation: A meta-analysis. BMC Cardiovasc. Disord., 22.","DOI":"10.1186\/s12872-022-02563-3"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cjca.2019.05.003","article-title":"Routine glycoprotein IIb\/IIIa inhibitor therapy in st-segment elevation myocardial infarction: A meta-analysis","volume":"35","author":"Karathanos","year":"2019","journal-title":"Can. J. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40560-020-00502-y","article-title":"Glycoprotein IIb\/IIIa Inhibitors for Cardiogenic Shock Complicating Acute Myocardial Infarction: A Systematic Review, Meta-Analysis, and Meta-Regression","volume":"8","author":"Saleiro","year":"2020","journal-title":"J. Intensive Care"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/jama.2022.0358","article-title":"Diagnosis and treatment of acute coronary syndromes: A review","volume":"327","author":"Bhatt","year":"2022","journal-title":"JAMA"},{"key":"ref_79","unstructured":"Singh, A., Museedi, A.S., and Grossman, S.A. (2022). StatPearls, StatPearls."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)02391-6","article-title":"Acute coronary syndromes","volume":"399","author":"Bergmark","year":"2022","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"PURSUIT Trial Investigators (1998). Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators Inhibition of Platelet Glycoprotein IIb\/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes. N. Engl. J. Med., 339, 436\u2013443.","DOI":"10.1056\/NEJM199808133390704"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ahj.2006.06.003","article-title":"Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for st-segment elevation myocardial infarction: Results of the time to integrilin therapy in acute myocardial infarction (TITAN)-TIMI 34 trial","volume":"152","author":"Gibson","year":"2006","journal-title":"Am. Heart J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMoa0706816","article-title":"Facilitated PCI in patients with ST-elevation myocardial infarction","volume":"358","author":"Ellis","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1016\/j.jacc.2009.11.091","article-title":"Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome","volume":"55","author":"Dill","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the european society of cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Kanic, V., Kompara, G., and Suran, D. (2022). GP IIb\/IIIa receptor inhibitors in mechanically ventilated patients with cardiogenic shock due to myocardial infarction in the era of potent P2Y12 receptor antagonists. J. Clin. Med., 11.","DOI":"10.3390\/jcm11247426"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Myrda, K., G\u0105sior, M., Dudek, D., Nawrotek, B., Niedziela, J., Wojakowski, W., Gierlotka, M., Grygier, M., St\u0119pi\u0144ska, J., and Witkowski, A. (2021). One-year outcome of glycoprotein IIb\/IIIa inhibitor therapy in patients with myocardial infarction-related cardiogenic shock. J. Clin. Med., 10.","DOI":"10.3390\/jcm10215059"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/heartjnl-2019-315707","article-title":"Recent advances in percutaneous coronary intervention","volume":"106","author":"Hoole","year":"2020","journal-title":"Heart"},{"key":"ref_89","unstructured":"Ahmad, M., Mehta, P., Reddivari, A.K.R., and Mungee, S. (2022). StatPearls, StatPearls Publishing."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes: Executive summary","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Impact-II Investigators (1997). Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet, 349, 1422\u20131428.","DOI":"10.1016\/S0140-6736(96)10172-0"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes","volume":"360","author":"Giugliano","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/1570161116666180117102422","article-title":"What is the role for glycoprotein IIb\/IIIa inhibitor use in the catheterization laboratory in the current era?","volume":"16","author":"Rubboli","year":"2018","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.amjcard.2011.06.039","article-title":"Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb\/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome","volume":"108","author":"Friedland","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_97","first-page":"67","article-title":"The effect of intracoronary versus intralesional injection of eptifibatide on myocardial perfusion outcomes during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction; a randomized clinical trial study","volume":"15","author":"Ghazal","year":"2019","journal-title":"ARYA Atheroscler."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1177\/1060028018824640","article-title":"Perioperative bridging with glycoprotein IIb\/IIIa Inhibitors versus cangrelor: Balancing efficacy and safety","volume":"53","author":"Newsome","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.carrev.2018.11.018","article-title":"Intravenous antiplatelet therapy bridging in patients undergoing cardiac or non-cardiac surgery following percutaneous coronary intervention","volume":"20","author":"Dargham","year":"2019","journal-title":"Cardiovasc. Revascularization Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/FJC.0000000000001192","article-title":"Safety and Efficacy of Periprocedural Bridging With Cangrelor Versus Eptifibatide","volume":"79","author":"Yun","year":"2022","journal-title":"J. Cardiovasc. Pharm."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"939215","DOI":"10.3389\/fneur.2022.939215","article-title":"Eptifibatide use in ischemic stroke patients undergoing endovascular thrombectomy: A matched cohort analysis","volume":"13","author":"Rana","year":"2022","journal-title":"Front. Neurol"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1161\/STROKEAHA.121.036754","article-title":"Combined approach to eptifibatide and thrombectomy in acute ischemic stroke because of large vessel occlusion: A matched-control analysis","volume":"53","author":"Ma","year":"2022","journal-title":"Stroke"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"105021","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105021","article-title":"Eptifibatide use following emergent carotid stenting in acute anterior circulation ischemic stroke with tandem occlusion","volume":"29","author":"Osteraas","year":"2020","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jocn.2020.11.048","article-title":"Adjunctive treatment with low dose intra-arterial eptifibatide and intravenous aspirin during carotid stenting: A case series","volume":"84","author":"Horev","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/ajhp\/zxab380","article-title":"The pathophysiology of sepsis-2021 update: Part 1, immunology and coagulopathy leading to endothelial injury","volume":"79","author":"Jacobi","year":"2022","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/1573403X1103150514155757","article-title":"Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney disease","volume":"11","author":"Agrawal","year":"2015","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"191","DOI":"10.14740\/cr357w","article-title":"Eptifibatide and cirrhosis: Rethinking GPIIb-IIIa inhibitors for acute coronary syndrome in the setting of liver dysfunction","volume":"5","author":"Weinreich","year":"2014","journal-title":"Cardiol. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa Inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e28243","DOI":"10.1097\/MD.0000000000028243","article-title":"Eptifibatide-induced acute profound thrombocytopenia: A case report","volume":"101","author":"Alamin","year":"2022","journal-title":"Medicine"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/20009666.2021.1871802","article-title":"A rare case of eptifibatide-induced thrombocytopenia","volume":"11","author":"Kamar","year":"2021","journal-title":"J. Community Hosp. Intern. Med. Perspect."},{"key":"ref_111","first-page":"e29549","article-title":"Eptifibatide-induced severe thrombocytopenia after ST-elevation myocardial infarction (STEMI): A case report","volume":"14","author":"Gheith","year":"2022","journal-title":"Cureus"},{"key":"ref_112","first-page":"e8817067","article-title":"Acute profound thrombocytopenia induced by eptifibatide causing diffuse alveolar hemorrhage","volume":"2021","author":"Byrd","year":"2021","journal-title":"Case Rep. Crit. Care"},{"key":"ref_113","first-page":"bcr-2017","article-title":"Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention","volume":"2017","author":"Golden","year":"2017","journal-title":"Case Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.cjca.2014.12.034","article-title":"Thrombocytopenia in acute coronary syndromes: Etiologies and proposed management","volume":"31","author":"Sharma","year":"2015","journal-title":"Can. J. Cardiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1172\/JCI36745","article-title":"Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin Beta3 cytoplasmic domain","volume":"119","author":"Gao","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"55","DOI":"10.21307\/immunohematology-2019-099","article-title":"Drug-induced immune thrombocytopenia: Incidence, clinical features, laboratory testing, and pathogenic mechanisms","volume":"30","author":"Curtis","year":"2014","journal-title":"Immunohematology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1177\/10600280211006645","article-title":"Complications and management of eptifibatide-induced thrombocytopenia","volume":"55","author":"Masood","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"201","DOI":"10.34172\/jcvtr.2022.17","article-title":"Diffuse alveolar hemorrhage; an under-diagnosed and rare complication of glycoprotein IIb\/IIIa inhibitors","volume":"14","author":"Hekmat","year":"2022","journal-title":"J. Cardiovasc. Thorac. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5446\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:53:27Z","timestamp":1760122407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":118,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24065446"],"URL":"https:\/\/doi.org\/10.3390\/ijms24065446","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]}}}